<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729934</url>
  </required_header>
  <id_info>
    <org_study_id>KBS2018</org_study_id>
    <nct_id>NCT03729934</nct_id>
  </id_info>
  <brief_title>Ketones Supplementation and Postprandial Lipemia</brief_title>
  <official_title>Effects of Ketones Supplementation on Postprandial Lipemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study determines whether different forms of ketones supplemented prior to a meal lower
      the triglyceride (fat) content in the blood of overweight and obese individuals. Through a
      randomized crossover design, participants (n=15) will participate in each of the following
      three experimental groups (no treatment control, ketone ester, ketone salt), with a 5-14 day
      washout period between each experimental visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous studies conducted by the investigative team in rodents show that male mice fed a
      diet containing 30% ketone ester (by kcals) results in greater fecal content and energy loss.
      While the investigators are unsure of the exact macronutrient content of the energy loss, the
      hypothesis is that the energy excretion is attributed to lower fat absorption. In the context
      of this study, it's hypothesized that ketone salts and ketone esters (both available
      commercially and used for a variety of health-related claims) will reduce the absorption of
      dietary fats leading to lower circulating triglyceride concentrations if consumed prior to a
      high-fat mixed meal. If the hypothesis is correct, ketones supplementation could become a
      valuable strategy to reduce the rise in circulating triglycerides often present in obesity.
      Triglyceride concentrations in the blood following a meal have been linked to development of
      cardiovascular disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline plasma glucagon-like peptide 1 at 240 minutes</measure>
    <time_frame>0, 30, 60, 120, 180, and 240 minutes post-supplement consumption</time_frame>
    <description>Plasma levels of glucagon-like peptide 1 in pg/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline serum triglycerides at 240 minutes</measure>
    <time_frame>0, 30, 60, 120, 180, and 240 minutes post-supplement consumption</time_frame>
    <description>Serum levels of triglycerides in mg/DL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline serum glucose at 240 minutes</measure>
    <time_frame>0, 30, 60, 120, 180, and 240 minutes post-supplement consumption</time_frame>
    <description>Serum levels of glucose in mg/dL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline serum Insulin at 240 minutes</measure>
    <time_frame>0, 30, 60, 120, 180, and 240 minutes post-supplement consumption</time_frame>
    <description>Serum levels of insulin in pmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline serum B-hydroxybutyrate at 240 minutes</measure>
    <time_frame>0, 30, 60, 120, 180, and 240 minutes post-supplement consumption</time_frame>
    <description>Serum levels of B-hydroxybutyrate in mmol/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline plasma ghrelin at 240 minutes</measure>
    <time_frame>0, 30, 60, 120, 180, and 240 minutes post-supplement consumption</time_frame>
    <description>Plasma levels of ghrelin in pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline plasma leptin at 240 minutes</measure>
    <time_frame>0, 30, 60, 120, 180, and 240 minutes post-supplement consumption</time_frame>
    <description>Plasma levels of leptin in ng/mL</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight and Obesity</condition>
  <condition>Overweight</condition>
  <condition>Triglycerides High</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This arm receives no treatment control.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketone Ester</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm receives 25 g ketone ester.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ketone Salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This arm receives 25 g ketone salt.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketone Ester</intervention_name>
    <description>This arm receives 25 g ketone ester.</description>
    <arm_group_label>Ketone Ester</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ketone Salt</intervention_name>
    <description>This arm receives 25 g ketone salt.</description>
    <arm_group_label>Ketone Salt</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overweight or obese men as defined by a BMI of greater than or equal to 25 kg/m2, but
             less than 35 kg/m2

          -  Between the ages of 25 and 45 years

          -  Fasting triglyceride levels less than 250 mg/dL

        Exclusion Criteria:

          -  Participates in regular physical activity (â‰¥3 days/week at 30 minutes or more per day)

          -  Diagnosed cardiovascular disease or metabolic disease (type 1 or type 2 diabetes)

          -  Currently following a low carbohydrate (&lt;100 g/day) diet

          -  Lost greater than or equal to 5% body weight over the last 2 months

          -  Alcohol/smoking/antibiotics
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 23, 2018</study_first_submitted>
  <study_first_submitted_qc>November 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Eric P. Plaisance</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

